Rate Contract for Medicines

Rate contracts for medicines are centralised or state-level standing agreements between government health authorities and pharmaceutical companies at fixed prices for defined medicines, allowing government hospitals, health centres, and public health programmes to procure drugs by issuing simple Release Orders without running individual tenders for each purchase. They are the backbone of India's public sector drug procurement.

What are Rate Contracts for Medicines in government procurement?

India's public health system procures medicines through a combination of centralised and decentralised mechanisms. At the national level, the Central Medical Services Society (CMSS), operating under the Ministry of Health and Family Welfare, manages centralised procurement of essential medicines and distributes them to states and union territories for national health programme requirements. State Medicines Corporations, such as Tamil Nadu Medical Services Corporation (TNMSC), Rajasthan Medical Services Corporation (RMSC), Kerala Medical Services Corporation (KMSCL), and equivalents in other states, manage state-level medicine procurement.

The rate contract process works as follows. The procuring body publishes a tender specifying the required medicines, identified by generic name (International Non-Proprietary Name or INN), formulation, strength, and packaging. Pharmaceutical manufacturers and their authorised distributors submit bids. The rate contract is awarded to one or more suppliers at the L1 price for each medicine, with the rate fixed for 1-2 years. Hospitals and health facilities then place Release Orders against the rate contract throughout the year.

TNMSC's model is widely regarded as a benchmark. Tamil Nadu procures 519 essential medicines centrally, achieving prices significantly below the open market because of aggregated volume, direct manufacturer participation (no middlemen), rigorous quality testing at the TNMSC's own laboratory, and strong performance monitoring. The success of TNMSC's model has been studied and adapted by other states.

For national health programmes, Pradhan Mantri Jan Aushadhi Pariyojana (affordable generic medicines through Jan Aushadhi stores), PM-ABHIM scheme, and emergency procurement, CMSS maintains centralised contracts that provide medicines to all states without state-level procurement overhead.

Quality assurance is integral to medicine rate contracts. All medicines supplied under government rate contracts must be from licensed manufacturers, tested at NABL-accredited laboratories, and must meet Schedule M compliance under the Drugs and Cosmetics Act 1940. Batches failing quality tests are recalled at the supplier's cost.

Why it matters for bidders

For pharmaceutical companies, winning a government rate contract for a medicine provides stable, predictable volume that helps amortise manufacturing fixed costs, improving margins elsewhere. TNMSC and CMSS rate contracts are won by quality manufacturers at competitive prices, but the volumes can justify prices below what the open market would sustain.

Generic drug manufacturers with WHO-GMP certified manufacturing, Schedule M compliance, and competitive cost structures are well-positioned for government rate contracts. The qualification requirements (drug licence, cGMP compliance, stability data, bioequivalence data for certain formulations) are demanding but achievable for any legitimate pharmaceutical manufacturer.

The competitive dynamics are intense. Rate contracts are L1, the generic drug market means many manufacturers can produce the same molecule, driving prices to thin margins. Companies must accurately model their cost of goods, compliance overhead, and delivery logistics before bidding.

Example

Rajasthan Medical Services Corporation (RMSC) floats a rate contract tender for 250 essential medicines to supply 7,000 government health facilities across the state over 2 years. For "Metformin 500mg tablets" (one of the listed medicines), 8 pharmaceutical companies bid. The L1 price is Rs 0.48 per tablet. RMSC awards the rate contract to the L1 bidder for the full state requirement (estimated 40 million tablets over 2 years). Individual hospitals and PHCs place Release Orders against the RMSC contract as stock depletes, the manufacturer supplies directly to district drug warehouses. Each batch is tested at RMSC's laboratory before release to facilities.

Key rules / thresholds

All medicines supplied under government rate contracts must comply with the Drugs and Cosmetics Act 1940 and Drugs and Cosmetics Rules 1945. Manufacturers must hold a valid drug manufacturing licence (Form 25 or Form 28) from the state licencing authority. WHO-GMP or Schedule M compliance is required for systemic medicines (tablets, injectables, capsules). Any batch failing quality testing under the rate contract must be recalled within 72 hours, and the supplier bears all replacement costs plus penalties specified in the contract.